- CP671305
-
- $31.00 / 1mg
-
2025-04-30
- CAS:445295-04-5
- Min. Order:
- Purity: 99.22%
- Supply Ability: 10g
|
| | CP671305 Basic information |
| Product Name: | CP671305 | | Synonyms: | CP671305;CP-671305; CP 671305; CP671305; UNII-9LH034R9R9;445295-04-5;UNII-9LH034R9R9;CS-2886;Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, (2R)-;(R)-2-(4-((2-(benzo[d][1,3]dioxol-5-yloxy)nicotinamido)methyl)-3-fluorophenoxy)propanoic acid;CP 671305,Inhibitor,Phosphodiesterase (PDE),CP671305,CP-671305,inhibit;CP671305, 10 mM in DMSO | | CAS: | 445295-04-5 | | MF: | C23H19FN2O7 | | MW: | 454.4 | | EINECS: | | | Product Categories: | API | | Mol File: | 445295-04-5.mol |  |
| | CP671305 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 50 mg/ml; DMSO: 25 mg/ml; Ethanol: 3 mg/ml; PBS (pH 7.2): 2 mg/ml | | form | A crystalline solid | | color | White to off-white |
| | CP671305 Usage And Synthesis |
| Description | CP 671,305 is a potent inhibitor of phosphodiesterase 4D (PDE4D; IC50 = 3 nM). It is selective for PDE4D over PDE4A, -B, and -C (IC50s = 310, 287, and 3,858 nM, respectively), as well as over PDE1-3 and 5 (IC50s = >5,000 nM for all). CP 671,305 inhibits release of leukotriene E4 (LTE4; ) from eosinophils (IC50 = 52 nM) and LTB4 from neutrophils (IC50 = 106 nM). In vivo, CP 671,305 inhibits antigen-induced pulmonary eosinophil influx in cynomolgus monkeys in a dose-dependent manner. | | Uses | CP671305 is a potent, orally active, selective inhibitor of phosphodiesterase-4-D, and possesses high activities. | | in vivo | CP-671,305 pharmacokinetics are largely unaltered, and compromised biliary clearance of CP-671,305 is compensated by increased urinary clearance[1]. CP-671,305 demonstrates generally favourable pharmacokinetic properties, systemic plasma clearance after intravenous administration is low in Sprague-Dawley rats (9.60 ± 1.16 mL/min/kg), beagle dogs (2.90 ± 0.81 mL/min/kg) and cynomolgus monkeys (2.94 ± 0.87 mL/min/kg) resulting in plasma half-lives > 5 h. Moderate to high bioavailability in rats (43-80%), dogs (45%) and monkeys (26%) is observed after oral dosing. In rats, oral pharmacokinetics are dose dependent over the dose range studied (10 and 25 mg/kg)[2]. | | References | [1] Kalgutkar AS, et al. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human. Drug Metab Dispos. 2007 Nov;35(11):2111-8. Epub 2007 Aug 8. DOI:10.1124/dmd.107.016162
[2] Kalgutkar AS, et al. Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species. Xenobiotica. 2004 Aug;34(8):755-70. DOI:10.1080/00498250400005682 |
| | CP671305 Preparation Products And Raw materials |
|